Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dostarlimab + Niraparib in Platinum-Resistant Ovarian Cancer
NCT03955471Phase 2Terminated
- Start
- Oct 2019
- Primary completion
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dostarlimab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC). Primary endpoints: Objective Response Rate at 22 months and Objective Response Rate in PD-L1 Positive Participants at 22 months. Started Oct 2019; status: terminated.
02
Drugs
dostarlimab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03955471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03955471.